Breast Cancer Detection With Tc-99m Tetrofosmin

Pf, Rambaldi; Mansi, Luigi; Procaccini, E; F, Di Gregorio; E, Del Vecchio

doi:10.1097/00003072-199508000-00009

Cited by 52 publications

(10 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…99m Tc-tetrofosmin has been used in primary breast cancer detection after first being reported by Rambaldi et al [14][15][16][17][18][19][20][21][22]. Fenlon et al [15] reported 95.2% sensitivity, 91.3% specificity, 90.9% positive predictive and 95.4% negative predictive values of 99m Tctetrofosmin SMM in the detection of primary breast cancer.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Technetium-99m-Tetrofosmin Scintimammography in Suspected Breast Cancer Patients: A Comparison with Technetium-99m-MIBI

Kim

et al. 2000

Med Princ Pract

View full text Add to dashboard Cite

Objective: To investigate the diagnostic role of ^99mTc-tetrofosmin in the detection of primary breast cancer and axillary lymph node metastasis and to compare the findings with those of ^99mTc-MIBI. Methods: Forty-eight patients with clinically palpable masses or abnormal radiologic findings had ^99mTc-MIBI and ^99mTc-tetrofosmin scintimammographies (SMMs) after intravenous injections of 925 MBq of radiopharmaceuticals. The SMMs were correlated with histopathologic findings. Results: Thirty-three patients were diagnosed with breast cancer and 15 patients with benign breast diseases. The number of true positive, true negative, false positive, and false negative cases of ^99mTc-tetrofosmin SMM were 31, 10, 5, and 2, respectively. The sensitivity, specificity, positive predictive value and negative predictive value of ^99mTc-tetrofosmin SMM were 93.9, 66.7, 86.1 and 73.3%, respectively. The number of true positive, true negative, false positive, and false negative cases of ^99mTc-MIBI SMM was 29, 10, 5, and 4, respectively. The sensitivity, specificity, positive predictive value, and negative predictive value of ^99mTc-MIBI SMM were 87.8, 66.7, 85.3 and 73.3%, respectively. In assessment of axillary lymph node involvement, ^99mTc tetrofosmin SMM demonstrated 31.8, 100, 100, and 42.3% sensitivity, specificity, positive and negative predictive values, respectively. The sensitivity and specificity of ^99mTc-MIBI SMM was 22.7 and 100%. Positive and negative predictive values were 100 and 39.3%, respectively. One patient was false negative in both ^99mTc-MIBI and ^99mTc-tetrofosmin SMMs with a tumor size of 0.5 cm. Conclusion:^99mTc-tetrofosmin and ^99mTc-MIBI SMMs were noninvasive and useful in the detection of primary breast cancer and ^99mTc tetrofosmin was comparable to ^99mTc-MIBI in the detection of primary breast cancer. However, both radiopharmaceuticals had limited values in the assessment of axillary lymph node involvement.

show abstract

Section: Discussionmentioning

confidence: 99%

“…After the report of Rambaldi et al [14] of increased 99m Tc-tetrofosmin uptake in breast cancer patients who had undergone myocardial perfusion imaging, it was investigated in various tumors. With respect to cost, 99m Tctetrofosmin and 99m Tc-MIBI are similar.…”

Section: Introductionmentioning

confidence: 99%

Technetium-99m-Tetrofosmin Scintimammography in Suspected Breast Cancer Patients: A Comparison with Technetium-99m-MIBI

Kim

et al. 2000

Med Princ Pract

View full text Add to dashboard Cite

show abstract

“…The first report of avid 99m Tcsestamibi uptake in breast cancer is by Aktolun et al in 1992. 12 99m Tc-tetrofosmin, with properties very similar to 99m Tc-sestamibi, was another technetium-labeled radiopharmaceutical developed for perfusion imaging reported to have avid uptake in breast tumors. 13 These serendipitous discoveries of radiopharmaceutical uptake in breast cancer led to the development of scintimammography, the name given to nuclear medicine breast imaging performed with scintillating gamma cameras. The gamma cameras utilized for scintimammography were the same large field-of-view conventional gamma cameras used for nuclear cardiology and general nuclear medicine imaging.…”

Section: Early Development Of Nuclear Breast Imagingmentioning

confidence: 99%

Nuclear imaging of the breast: Translating achievements in instrumentation into clinical use

Hruska

O’Connor

2013

Medical Physics

View full text Add to dashboard Cite

Approaches to imaging the breast with nuclear medicine and/or molecular imaging methods have been under investigation since the late 1980s when a technique called scintimammography was first introduced. This review charts the progress of nuclear imaging of the breast over the last 20 years, covering the development of newer techniques such as breast specific gamma imaging, molecular breast imaging, and positron emission mammography. Key issues critical to the adoption of these technologies in the clinical environment are discussed, including the current status of clinical studies, the efforts at reducing the radiation dose from procedures associated with these technologies, and the relevant radiopharmaceuticals that are available or under development. The necessary steps required to move these technologies from bench to bedside are also discussed.

show abstract

“…In 1995, Rambaldi et al [2] described the incidental detection of abnormal uptake in a patient with breast cancer undergoing myocardial scintigraphy with TF. Besides breast cancer, TF has been considered a radiopharmaceutical with a great deal of promise in the imaging of different cancers [3,4].…”

Section: Introductionmentioning

confidence: 99%

Evaluation of morphine effect on tumour angiogenesis in mouse breast tumour model, EATC

et al. 2010

View full text Add to dashboard Cite

Breast cancer is the leading cause of death among women, and morphine is used to relieve the pain of patients with cancer. The data on the effects of morphine on tumour growth and angiogenesis are contradictory. We determined in mouse breast cancer model whether analgesic doses of morphine would affect tumour angiogenesis, and then the correlation between microvessel density (MVD), Doppler sonography (DS) and 99mTc-Tetrofosmin (TF) uptake. Ehrlich ascites tumour cell xenografts, Pgp-negative tumour were divided into two groups: (a) Morphine sulphate [0.714 mg/kg/day (equivalent to 50 mg per day for a 70 kg human)], (b) no-morphine. For the determination of angiogenesis in mice tumour tissue, TF scintigraphy, microvessel density and DS were done. MVD was significantly different between groups (49.4±1.8 vs. 41.8±1.9, morphine and no-morphine groups, respectively, P<0.001). A strong correlation was found between late uptakes of mass at scintigraphy and degree of angiogenesis in histopathologic examination (r=0.52, P<0.01). There was statistically significant inverse correlation between degree of angiogenesis in histopathologic examination and washout ratio of TF (r=0.40, P<0.05). The higher values for angiogenesis are related to higher TF reuptake. There was no statistically significant correlation between DS and TF. A strong correlation was found between MVD and grade of DS (r=0.51, P<0.01). Our preclinical mice study indicates that morphine at clinically relevant doses stimulates angiogenesis, and angiogenesis triggered of morphine is demonstrated with MVD and DS, but not TF. However, uptake and washout of TF are compared with immunohistochemically assessed morphine-stimulated angiogenesis in tumour tissue.

show abstract

Breast Cancer Detection With Tc-99m Tetrofosmin

Cited by 52 publications

References 0 publications

Technetium-99m-Tetrofosmin Scintimammography in Suspected Breast Cancer Patients: A Comparison with Technetium-99m-MIBI

Technetium-99m-Tetrofosmin Scintimammography in Suspected Breast Cancer Patients: A Comparison with Technetium-99m-MIBI

Nuclear imaging of the breast: Translating achievements in instrumentation into clinical use

Evaluation of morphine effect on tumour angiogenesis in mouse breast tumour model, EATC

Contact Info

Product

Resources

About